Pyxis Oncology is trading 6.17% up in after-hours trading at $4.13 after announcing Thomas Civik’s appointment as permanent CEO and chairman, effective September 4, 2026.
- Civik served as interim CEO since February; co-founder John Flavin transitions to lead independent director.
- Leadership clarification appears to be the primary company-specific catalyst behind the gain.
- Trading has been volatile, with sharp recent daily moves; broader markets declined on September 8, 2026, making macro sentiment a modest offset.